2024
Radiotherapy Plan Quality Assurance in NRG Oncology Trials for Brain and Head/Neck Cancers: An AI-Enhanced Knowledge-Based Approach
Wang D, Geng H, Gondi V, Lee N, Tsien C, Xia P, Chenevert T, Michalski J, Gilbert M, Le Q, Omuro A, Men K, Aldape K, Cao Y, Srinivasan A, Barani I, Sachdev S, Huang J, Choi S, Shi W, Battiste J, Wardak Z, Chan M, Mehta M, Xiao Y. Radiotherapy Plan Quality Assurance in NRG Oncology Trials for Brain and Head/Neck Cancers: An AI-Enhanced Knowledge-Based Approach. Cancers 2024, 16: 2007. PMID: 38893130, PMCID: PMC11171017, DOI: 10.3390/cancers16112007.Peer-Reviewed Original ResearchIntensity-modulated proton therapyPlan quality assuranceOrgan-at-riskRT planningQuality of radiation therapyClinical trialsIMPT plansKBP modelPlan QAPhoton plansRadiation therapyPhoton modelKBP plansTarget coveragePlan qualityProton therapyNasopharyngeal carcinomaMulti-institutional clinical trialsNRG Oncology trialsProton modelOutcomes of clinical trialsMulti-center clinical trialPhoton RTQuality assuranceHead/neck cancer
2022
Axillary Nodal Response to Neoadjuvant T-DM1 Combined with Pertuzumab in a Prospective Phase II Multi-Institution Clinical Trial
Weiss A, King T, Krop I, Filho O. Axillary Nodal Response to Neoadjuvant T-DM1 Combined with Pertuzumab in a Prospective Phase II Multi-Institution Clinical Trial. Journal Of The American College Of Surgeons 2022, 235: s5-s5. DOI: 10.1097/01.xcs.0000895628.64012.95.Peer-Reviewed Original ResearchMulti-institutional clinical trials
2021
Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patients
Paoletti C, Regan MM, Niman SM, Dolce EM, Darga EP, Liu MC, Marcom PK, Hart LL, Smith JW, Tedesco KL, Amir E, Krop IE, DeMichele AM, Goodwin PJ, Block M, Aung K, Brown ME, McCormack RT, Hayes DF. Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patients. Npj Breast Cancer 2021, 7: 77. PMID: 34117261, PMCID: PMC8196036, DOI: 10.1038/s41523-021-00281-1.Peer-Reviewed Original ResearchMetastatic breast cancerProgression-free survivalER-positive metastatic breast cancerHER2-negative metastatic breast cancerWorse progression-free survivalWhole bloodTherapy indexExact testPositive metastatic breast cancer patientsMedian progression-free survivalMetastatic breast cancer patientsHuman epidermal growth factor receptorMulti-institutional clinical trialsGroup of patientsBreast cancer patientsSerial time pointsFisher's exact testTumor cell numberEpidermal growth factor receptorElevated CTCsGrowth factor receptorPrimary endpointClinical outcomesCancer patientsClinical trials
2020
Intraaortic Balloon Pump vs Peripheral Ventricular Assist Device Use in the United States
Sanaiha Y, Ziaeian B, Antonios J, Kavianpour B, Anousheh R, Benharash P. Intraaortic Balloon Pump vs Peripheral Ventricular Assist Device Use in the United States. The Annals Of Thoracic Surgery 2020, 110: 1997-2005. PMID: 32454014, PMCID: PMC7687352, DOI: 10.1016/j.athoracsur.2020.03.129.Peer-Reviewed Original ResearchConceptsInverse probability of treatment weightingIntraaortic balloon pumpProbability of treatment weightingPercutaneous left ventricular assist deviceAdverse eventsAssistive device useCardiogenic shockPatients admitted with cardiogenic shockInverse probabilitySurvey-weighted estimatesComposite of adverse eventsOdds of mortalityTreatment weightingStudy periodCochran-Armitage testNational Inpatient SampleRisk-adjusted analysisMultivariate regression modelBalloon pumpAssociated with increased mortalityIntraaortic balloon pump useMulti-institutional clinical trialsInclusion criteriaDevice useInpatient Sample
2017
Risk of complications and urinary incontinence following cytoreductive prostatectomy: a multi-institutional study
Kim DK, Parihar JS, Kwon YS, Kim S, Shinder B, Lee N, Farber N, Ahlering T, Skarecky D, Yuh B, Ruel N, Kim WJ, Rha KH, Kim IY. Risk of complications and urinary incontinence following cytoreductive prostatectomy: a multi-institutional study. Asian Journal Of Andrology 2017, 20: 9-14. PMID: 28440262, PMCID: PMC5753561, DOI: 10.4103/1008-682x.196852.Peer-Reviewed Original ResearchConceptsMetastatic prostate cancerCytoreductive prostatectomyUrinary incontinenceProstate cancerBlood lossRadical prostatectomyCare androgen-deprivation therapyBenefit of cytoreductionUrinary incontinence rateAndrogen deprivation therapyMulti-institutional clinical trialsIncidence of complicationsMajor complication rateOnly independent predictorLonger operative timeRisk of complicationsTertiary surgical centerMulti-institutional studyDeprivation therapyBony metastasesIncontinence ratesPerioperative complicationsComplication rateCRP groupIndependent predictors
2011
Cancer and Leukemia Group B Pathology Committee Guidelines for Tissue Microarray Construction Representing Multicenter Prospective Clinical Trial Tissues
Rimm DL, Nielsen TO, Jewell SD, Rohrer DC, Broadwater G, Waldman F, Mitchell KA, Singh B, Tsongalis GJ, Frankel WL, Magliocco AM, Lara JF, Hsi ED, Bleiweiss IJ, Badve SS, Chen B, Ravdin PM, Schilsky RL, Thor A, Berry DA. Cancer and Leukemia Group B Pathology Committee Guidelines for Tissue Microarray Construction Representing Multicenter Prospective Clinical Trial Tissues. Journal Of Clinical Oncology 2011, 29: 2282-2290. PMID: 21519016, PMCID: PMC3107745, DOI: 10.1200/jco.2010.33.2023.Peer-Reviewed Original ResearchConceptsMulti-institutional clinical trialsPractice-changing evidenceProportion of patientsCooperative Oncology GroupCooperative group studiesCompanion diagnostic testsCollection of tissuesOncology GroupClinical trialsPathology CommitteeStudy populationCommittee guidelinesSuch trialsDiagnostic testsBiomarker studiesGroup studyPrecious tissuePatientsCancerTissueNumber of assaysTrialsFacility directorsGuidelines
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply